iRhythm Technologies Announces Chief Financial Officer Transition
01 Agosto 2024 - 3:06PM
iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health
care company focused on creating trusted solutions that detect,
predict, and prevent disease, announced today that Brice Bobzien,
Chief Financial Officer, will step down for personal reasons
effective August 31, 2024. He will be succeeded by Daniel Wilson,
iRhythm’s current Executive Vice President of Corporate Development
and Investor Relations. Mr. Bobzien has served as the CFO since
2022, and he will continue to serve the Company in an advisory
capacity into 2025 following the succession to ensure a smooth
transition.
“Brice has been an outstanding leader at iRhythm over the past
two years, making significant contributions to transform iRhythm’s
finance organization during his tenure with the company,” said
Quentin Blackford, iRhythm’s President and CEO. “He has been
invaluable in helping position our company to operate efficiently
and effectively ahead of immense growth, leading with a disciplined
and rigorous approach to financial management, operational
excellence, and strategic development. We wish him all the best as
he shifts his attention towards personal and family matters.”
“At the same time, we are thrilled to have Dan take over the
finance organization and are confident in the expanded leadership
he will provide as our next CFO. Dan has a long history with
iRhythm, advising the company on its initial public offering and
then joining iRhythm in 2019. In his time with the company, Dan has
been a trusted partner, strategic leader, unwavering brand
ambassador, and a passionate champion of iRhythm’s mission. His
strong strategic background, industry experience, and financial
acumen make him uniquely qualified to help lead the organization
into our next phase of growth.”
Mr. Wilson has served as iRhythm’s Executive Vice President of
Corporate Development and Investor Relations since April 2023 and
previously served as Executive Vice President of Corporate
Development, Corporate Strategy, and Investor Relations since June
2019. Previously, he served as Director and Head of Business
Development at Penumbra, Inc., a global healthcare company focused
on innovative therapies. Prior to Penumbra, he held various
positions at J.P. Morgan between August 2006 and May 2016, most
recently as Executive Director in the Healthcare Investment Banking
group focused on digital health, medical technology, and emerging
healthcare companies. Earlier in his career, he held various
positions in Piper Jaffray’s Healthcare Investment Banking group.
He started his career at KPMG as an Audit Associate. Mr. Wilson has
a B.S. in Business Administration from California Polytechnic State
University at San Luis Obispo.
About iRhythm Technologies, Inc.iRhythm is a
leading digital health care company that creates trusted solutions
that detect, predict, and prevent disease. Combining wearable
biosensors and cloud-based data analytics with powerful proprietary
algorithms, iRhythm distills data from millions of heartbeats into
clinically actionable information. Through a relentless focus on
patient care, iRhythm’s vision is to deliver better data, better
insights, and better health for all.
Investor Relations ContactStephanie
Zhadkevichinvestors@irhythmtech.com
Media ContactKassandra
Perryirhythm@highwirepr.com
iRhythm Technologies (NASDAQ:IRTC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
iRhythm Technologies (NASDAQ:IRTC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024